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The patient, "PS," was an 83-year-old white female who presented at Bastyr University, Kenmore, Washington, and Swedish Cancer Institute, Seattle, in June 2009 with advanced, metastatic inflammatory breast cancer. The patient had a large mass in her right breast with significant lymphedema and swelling, redness, and dermal invasion. The tumor had invaded the chest wall, right shoulder, and back with metastasis to the bone, liver, and lymph nodes. At the time of her diagnosis, her prognosis was poor with a life expectancy of a few years even with medical interventions. Physicians at Swedish Cancer Institute performed a needle biopsy that revealed that her tumor was HER2-neu--positive. Her baseline laboratory values (June 25, 2009) were normal with the exception of alkaline phosphatase, which was 179 U/L (normal: 32-91); AST, which was 52 IU/L (normal: 15-41); albumin, 3.0 (normal 3.5-4.8), and hematocrit, 35.5% (normal: 36.0-46.0). Her HER2 score was 3+. A baseline cardiac evaluation showed a normal ejection fraction and no cardiac abnormalities.

PS had no risk factors for breast cancer. Specifically, she had five normal pregnancies beginning at age 22, no family history of breast cancer, normal mammograms, and no history of prolonged hormone replacement therapy during menopause. At the time of her diagnosis, PS was taking multivitamins and a mushroom supplement. Her medical history was significant for degenerative arthritis (PS walks with a cane). Additionally, PS lives in an actively spiritual community from which she received much support before, during, and after her cancer treatment.

After the diagnosis of HER2-neu--positive breast cancer, I began treating PS in Wenatchee, Washington. In June 2009, I began weekly treatment with a chemo-therapy regime of paclitaxel (Taxol) and trastuzumab (Herceptin). PS had a positive clinical response within several weeks and continued to have a steady positive response over the next 6 months with dramatic reduction in lymph node enlargement, swelling, redness, and skin involvement. PS also noted steady improvement, and by December 2009, she had minimal disease. The two-drug chemotherapy was continued for two cycles past her best response, and then maintenance therapy was initiated. In December 2009, the paclitaxel was discontinued and the trastuzumab was administered every 3 weeks as maintenance therapy, which PS continues to receive.

Trastuzumab is a monoclonal antibody that down-regulates the HER2-neu receptor and is used in the treatment of certain types of breast cancer.[@R1] HER2 is over-expressed in the cells of some breast cancer patients. Trastuzumab binds to the HER2 protein and interferes with its ability to stimulate reproduction of cells in the breast. It also suppresses angiogenesis. The original research studies of trastuzumab showed that it modestly improved overall survival in late-stage meta-static breast cancer.

Although trastuzumab is often well tolerated by patients regardless of age, potential side effects may include flu-like symptoms of fever/chills, muscle aches, and nausea. Some patients also experience congestive heart failure, lung toxicity, or an allergic reaction to the medication that causes wheezing. The majority of patients receiving trastuzumab remain functional and do not develop cytopenia or infections. PS had no significant comorbidities at the onset of chemotherapy, experienced no side effects, and had no clinical evidence of cardiomyopathy during treatment.

There is a risk of neuropathy developing in any patient treated with paclitaxel, which increases with longer duration of therapy. At the onset of treatment, PS had substantial cancer-related symptoms, and these symptoms resolved within the first 6 months of treatment with paclitaxel and trastuzumab. Elderly patients with a good performance status and no comorbidities often respond well to treatment, and age should not be considered a factor with regard to treatment decisions.

It has been well documented in the medical literature that patients often conceal medical treatments from their practitioners. This was true in this case as well. PS had been taking a general mushroom supplement at the time of her diagnosis. While undergoing chemotherapy, PS began taking turkey tail mushrooms. Fortunately, in this patient\'s case, she had apparent no adverse events or interactions between her chemotherapy treatment and medicinal mushrooms. The global convergence and integration of systems-oriented approaches will require new partnership models for patients and their providers. We are all grateful for this patient\'s extremely positive treatment response. PS has had no relapse and remains in clinical remission with no evidence of disease. Repeat computed tomography and bone scans show no evidence of metastasized cancer, and the patient\'s physical exam is normal. Presently, I see PS every 3 months, and a nurse practitioner administers trastuzumab infusions from at a rural treatment center closer to her home every 3 weeks.

DISCUSSION
==========

-   As an oncologist unfamiliar with medicinal mushrooms, I do not know what role, if any, the turkey tail mushroom therapy played in her response.

-   I have seen the type of clinical response experienced by PS in other patients with HER2-neu--overexpressing breast cancer receiving targeted therapy with Herceptin.

-   I was unaware of PS\'s mushroom therapy until well after her treatment had been successful. The mushroom therapy turned out to not be a problem in this case; however, it is always better to have a complete understanding of what other medications and supplements a patient is taking during chemotherapy.

-   I support the patient\'s decision to actively participate in her religious community and to continue to take the medicinal mushroom supplements in conjunction with Herceptin maintenance and regular medical follow-ups.
